Cas:10403-80-2 3,5-dimethyl-1,2,4-oxadiazole manufacturer & supplier

Chemical Name:3,5-dimethyl-1,2,4-oxadiazole

CAS.NO:10403-80-2

Synonyms:3,5-Dimethyl-1,2,4-oxadiazol;3,5-Dimethyl-oxadiazol;DIMETHYL-1,2,4-OXADIAZOLE;1,2,4-Oxadiazole,3,5-dimethyl

Molecular Formula:C₄H₆N₂O

Molecular Weight:98.10320

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:38.92000

Exact Mass:98.04800

LogP:0.68640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,5-Dimethyl-1,2,4-oxadiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,4-Oxadiazole,3,5-dimethyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-Dimethyl-1,2,4-oxadiazol Use and application,1,2,4-Oxadiazole,3,5-dimethyl technical grade,usp/ep/jp grade.

Related News: The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses. 3,5-dimethyl-1,2,4-oxadiazole manufacturer Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 3,5-dimethyl-1,2,4-oxadiazole supplier I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. 3,5-dimethyl-1,2,4-oxadiazole vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 3,5-dimethyl-1,2,4-oxadiazole factory Huahai started with the development of characteristic APIs and pharmaceutical intermediates. At the same time, using the international cooperation platform and the opportunity of the expiry of patent protection of major international original research drugs, Huahai has extended the industrial chain to downstream high value-added preparations, and formed intermediates and materials The complete industrial chain of medicine and preparation integration.